SEATTLE, June 30, 2026
AGC Biologics has announced a strategic partnership with Pyramid Pharma Services to expand its U.S.-based fill-finish manufacturing capabilities, creating an integrated end-to-end manufacturing solution that spans drug substance development, sterile fill-finish, device assembly, labeling, and secondary packaging for clinical and commercial biopharmaceutical programs. The collaboration strengthens AGC Biologics’ contract development and manufacturing organization (CDMO) services by combining its expertise in mammalian and microbial biologics manufacturing with Pyramid Pharma Services’ nearly 40 years of sterile injectable drug product experience. The partnership provides pharmaceutical and biotechnology companies with a streamlined manufacturing pathway that reduces supply chain complexity, accelerates development timelines, and enhances manufacturing flexibility within the United States. As demand continues to rise for domestic biologics manufacturing and secure pharmaceutical supply chains, the collaboration positions both companies to support drug developers seeking efficient, integrated production from early clinical development through commercial-scale manufacturing.
Integrated U.S. Manufacturing Strengthens Drug Development
The strategic collaboration enables AGC Biologics to provide clients with comprehensive sterile fill-finish capabilities in the United States, including liquid and lyophilized vial filling, pre-filled syringes, cartridges, device assembly, labeling, and secondary packaging. By integrating drug substance manufacturing with drug product manufacturing under a coordinated development model, pharmaceutical companies can reduce operational complexity while improving project efficiency throughout the product lifecycle.
Instead of coordinating multiple manufacturing partners, developers will benefit from single-contract project management, reducing technology transfer risks and minimizing production delays. The partnership supports a wide range of biologic products and provides scalable manufacturing services capable of advancing programs from early clinical studies through commercial production, allowing developers to accelerate the delivery of innovative therapies to patients while maintaining high quality and regulatory compliance.
Strategic Partnership Enhances Supply Chain Flexibility
Advertisement
The addition of U.S.-based fill-finish operations complements AGC Biologics’ existing European manufacturing network, providing customers with greater geographic flexibility when designing global manufacturing strategies. The expanded service offering is expected to help pharmaceutical companies address evolving regulatory requirements, reduce exposure to international trade uncertainties, strengthen supply chain resilience, and support regional manufacturing preferences.
Pyramid Pharma Services contributes extensive expertise in sterile injectable formulation development, lyophilization, analytical testing, technology transfer, clinical manufacturing, and commercial fill-finish operations, backed by more than 26 years of GMP manufacturing experience and over a decade of commercial production. The combined capabilities create an integrated manufacturing ecosystem that simplifies product development while enabling sponsors to move efficiently between development milestones and commercial launch with consistent quality standards and operational oversight.
Collaboration Advances CDMO Innovation for Biopharma Industry
The partnership represents another important milestone in the evolution of integrated CDMO services, reflecting the pharmaceutical industry’s growing demand for comprehensive manufacturing solutions capable of reducing development risk and accelerating market access. As biologic medicines become increasingly complex, sponsors are seeking manufacturing partners that can deliver seamless support across every stage of development while maintaining regulatory excellence and manufacturing flexibility. AGC Biologics continues to strengthen its global manufacturing platform by expanding strategic collaborations that enhance both capacity and technical expertise.
Through its partnership with Pyramid Pharma Services, the company is positioned to offer drug developers a highly integrated solution combining drug substance manufacturing, sterile fill-finish, packaging, and device assembly within a streamlined operational framework. The collaboration reinforces AGC Biologics’ commitment to advancing biopharmaceutical manufacturing innovation while helping developers bring life-changing therapies to patients faster, more efficiently, and with greater supply chain security across the United States and Europe.
Source: AGC Biologics press release
